menu
    • menu

    Company profile for AC Immune

    NEW Drugs in Dev: 9
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerative diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AC ImmuneSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    EPFL Innovation Park Building B 1015 Lausanne
    Telephone
    Telephone
    +41 21 345 91 21
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.acimmune.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly Pays AC Immune $12.5M To Expand Alzheimer's Collab
    Lilly Pays AC Immune $12.5M To Expand Alzheimer's Collab

    07 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lilly-pays-ac-immune-125m-expand-alzheimers-collab-small-molecule-draws-closer-clinic

    FIERCE BIOTECH
    07 Apr 2026
    Share Share
    AC Immune Unveils TDP-43 Brain Pathology Images from ACI-19626
    AC Immune Unveils TDP-43 Brain Pathology Images from ACI-19626

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258867/0/en/AC-Immune-Presents-First-In-vivo-Images-of-Brain-TDP-43-Pathology-from-Phase-1-Trial-of-PET-tracer-ACI-19626-at-AD-PDTM-2026.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    AC Immune Reveals 2025 Financials, Updates Corporate Status
    AC Immune Reveals 2025 Financials, Updates Corporate Status

    13 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/13/3255371/0/en/AC-Immune-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    13 Mar 2026
    Share Share
    AC Immune To Host Parkinson's Disease Symposium At AD/PD 2026
    AC Immune To Host Parkinson's Disease Symposium At AD/PD 2026

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250015/0/en/AC-Immune-Announces-Upcoming-Industry-Symposium-on-Parkinson-s-Disease-and-Presentation-at-AD-PD-2026.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor
    AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243363/0/en/AC-Immune-Initiates-Phase-1-Clinical-Trial-of-NLRP3-Inhibitor.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    J&J Halts Enrollment in Trial of AC Immune Alzheimer's drug
    J&J Halts Enrollment in Trial of AC Immune Alzheimer's drug

    19 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy

    FIERCE BIOTECH
    19 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search